These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 8103046)
1. Mechanism of the enhanced intrinsic activity of single-chain urokinase-type plasminogen activator during ongoing fibrinolysis. Fleury V; Lijnen HR; Anglés-Cano E J Biol Chem; 1993 Sep; 268(25):18554-9. PubMed ID: 8103046 [TBL] [Abstract][Full Text] [Related]
2. Plasminogen activation with single-chain urokinase-type plasminogen activator (scu-PA). Studies with active site mutagenized plasminogen (Ser740----Ala) and plasmin-resistant scu-PA (Lys158----Glu). Lijnen HR; Van Hoef B; Nelles L; Collen D J Biol Chem; 1990 Mar; 265(9):5232-6. PubMed ID: 1969415 [TBL] [Abstract][Full Text] [Related]
3. Characterization of a fusion protein consisting of amino acids 1 to 263 of tissue-type plasminogen activator and amino acids 144 to 411 of urokinase-type plasminogen activator. Nelles L; Lijnen HR; Collen D; Holmes WE J Biol Chem; 1987 Aug; 262(22):10855-62. PubMed ID: 2956260 [TBL] [Abstract][Full Text] [Related]
4. The mechanism of plasminogen activation and fibrin dissolution by single chain urokinase-type plasminogen activator in a plasma milieu in vitro. Lijnen HR; Van Hoef B; De Cock F; Collen D Blood; 1989 May; 73(7):1864-72. PubMed ID: 2713507 [TBL] [Abstract][Full Text] [Related]
5. Characterization of recombinant human single chain urokinase-type plasminogen activator mutants produced by site-specific mutagenesis of lysine 158. Nelles L; Lijnen HR; Collen D; Holmes WE J Biol Chem; 1987 Apr; 262(12):5682-9. PubMed ID: 3106341 [TBL] [Abstract][Full Text] [Related]
6. Pro-urokinase: a study of its stability in plasma and of a mechanism for its selective fibrinolytic effect. Pannell R; Gurewich V Blood; 1986 May; 67(5):1215-23. PubMed ID: 3083889 [TBL] [Abstract][Full Text] [Related]
7. Structural and functional characterization of mutants of recombinant single-chain urokinase-type plasminogen activator obtained by site-specific mutagenesis of Lys158, Ile159 and Ile160. Lijnen HR; Nelles L; Van Hoef B; Demarsin E; Collen D Eur J Biochem; 1988 Nov; 177(3):575-82. PubMed ID: 2973984 [TBL] [Abstract][Full Text] [Related]
8. Differential inhibition of soluble and cell surface receptor-bound single-chain urokinase by plasminogen activator inhibitor type 2. A potential regulatory mechanism. Schwartz BS J Biol Chem; 1994 Mar; 269(11):8319-23. PubMed ID: 7907591 [TBL] [Abstract][Full Text] [Related]
9. Interaction of single-chain urokinase-type plasminogen activator with human endothelial cells. Barnathan ES; Kuo A; Rosenfeld L; Karikó K; Leski M; Robbiati F; Nolli ML; Henkin J; Cines DB J Biol Chem; 1990 Feb; 265(5):2865-72. PubMed ID: 2154462 [TBL] [Abstract][Full Text] [Related]
10. Biochemical properties of recombinant mutants of nonglycosylated single chain urokinase-type plasminogen activator. Li XK; Lijnen HR; Nelles L; Hu MH; Collen D Biochim Biophys Acta; 1992 Sep; 1159(1):37-43. PubMed ID: 1390910 [TBL] [Abstract][Full Text] [Related]
11. Characterization of a chimeric plasminogen activator consisting of amino acids 1 to 274 of tissue-type plasminogen activator and amino acids 138 to 411 of single-chain urokinase-type plasminogen activator. Lijnen HR; Nelles L; Van Hoef B; Demarsin E; Collen D J Biol Chem; 1988 Dec; 263(35):19083-91. PubMed ID: 3143723 [TBL] [Abstract][Full Text] [Related]
13. Comparative kinetic analysis of the activation of human plasminogen by natural and recombinant single-chain urokinase-type plasminogen activator. Lijnen HR; Van Hoef B; Collen D Biochim Biophys Acta; 1986 Dec; 884(3):402-8. PubMed ID: 3778931 [TBL] [Abstract][Full Text] [Related]
14. Characterization of a recombinant chimeric plasminogen activator with enhanced fibrin binding. Jiao J; Yu M; Ru B Biochim Biophys Acta; 2001 Apr; 1546(2):399-405. PubMed ID: 11295444 [TBL] [Abstract][Full Text] [Related]
15. Activation with plasmin of tow-chain urokinase-type plasminogen activator derived from single-chain urokinase-type plasminogen activator by treatment with thrombin. Lijnen HR; Van Hoef B; Collen D Eur J Biochem; 1987 Dec; 169(2):359-64. PubMed ID: 2961562 [TBL] [Abstract][Full Text] [Related]
16. Effect of fibrin-targeting on clot lysis with urokinase-type plasminogen activator. Lijnen HR; Dewerchin M; De Cock F; Collen D Thromb Res; 1990 Feb; 57(3):333-42. PubMed ID: 2107593 [TBL] [Abstract][Full Text] [Related]
17. Differences between neonates and adults in the urokinase-plasminogen activator (u-PA) pathway of the fibrinolytic system. Ries M; Zenker M; Gaffney PJ Thromb Res; 2000 Nov; 100(4):341-51. PubMed ID: 11113278 [TBL] [Abstract][Full Text] [Related]
18. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site. Colucci M; Cavallo LG; Agnelli G; Mele A; Bürgi R; Heim J; Semeraro N Thromb Haemost; 1993 May; 69(5):466-72. PubMed ID: 8391727 [TBL] [Abstract][Full Text] [Related]
19. Characterization of a recombinant fusion protein of the finger domain of tissue-type plasminogen activator with a truncated single chain urokinase-type plasminogen activator. Gheysen D; Lijnen HR; Piérard L; de Foresta F; Demarsin E; Jacobs P; De Wilde M; Bollen A; Collen D J Biol Chem; 1987 Aug; 262(24):11779-84. PubMed ID: 3114253 [TBL] [Abstract][Full Text] [Related]
20. The inactivation of single-chain urokinase-type plasminogen activator by thrombin on cultured human endothelial cells. Braat EA; Collen A; Jie AF; Grimbergen JM; Rijken DC Biochim Biophys Acta; 2000 Sep; 1497(3):351-8. PubMed ID: 10996659 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]